PVLA — PALVELLA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583648 ·
Last close
$139.04
Market Cap
$1.99B
52W High
$161.38
52W Low
$100.00
ADV30
281,677
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -14,855,000 | -15,767,000 | 263,759,000 | 206,394,000 | 31,446,000 |
| Dec 2025 | 0 | — | -11,304,000 | -12,714,000 | 59,559,000 | 57,982,000 | 31,576,000 |
| Sep 2025 | 0 | — | -10,177,000 | -11,345,000 | 66,937,000 | 63,567,000 | 28,255,000 |
| Jun 2025 | 0 | — | -9,250,000 | -9,471,000 | 73,747,000 | 70,433,000 | 25,967,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,006,000
Investing CF
—
Financing CF
$-660,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-135,450,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-35,897,000
Pretax Income TTM
$-41,715,000
Interest Exp TTM
$5,818,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,602,000 | -41,715,000 | 59,559,000 | 31,576,000 | — | -25,006,000 |
| Dec 2024 | 0 | -14,095,000 | -17,434,000 | 88,234,000 | 25,627,000 | — | -10,840,000 |
| Dec 2023 | 0 | -11,869,000 | 18,691,000 | 7,548,000 | 11,428,000 | — | -13,703,000 |
| Dec 2022 | 0 | -18,040,000 | -27,552,000 | 16,524,000 | 39,698,000 | — | -14,840,000 |
TTM Snapshot
Revenues TTM
$29,701,000
NetIncome TTM
$-38,526,000
OpCashFlow TTM
$0
Assets (Latest)
$153,560,000
Forward EPS
$-6.38
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | $1.98B | $31.44 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.97B | $10.01 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.96B | $40.98 | — |
| GRFS | Grifols SA | $2.03B | $7.87 | — |
| BHVN | Biohaven Ltd. | $2.03B | $13.50 | — |
News headlines (Yahoo Finance, 1h cache)
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
2026-07-30 11:30 · Yahoo
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
2026-07-28 11:30 · Yahoo
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN
2026-07-15 14:01 · Yahoo
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
2026-06-30 11:30 · Yahoo
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
2026-06-29 11:30 · Yahoo
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
2026-06-27 16:31 · Yahoo
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy
2026-06-22 12:49 · Yahoo
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
2026-06-22 11:30 · Yahoo
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum
2026-06-16 00:16 · Yahoo
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
2026-06-03 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.